Eli Lilly & Co. (LLY)
Eli Lilly & Co. is a global pharmaceutical company founded in 1876, focused on developing innovative medicines in areas such as oncology, neuroscience, diabetes, and immunology. The company is known for its research-driven approach and has a strong portfolio of prescription drugs and biologics aimed at improving patient health worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 10, 2025 | $1.50 | 2025-08-15 | 2025-08-15 |
| June 10, 2025 | $1.50 | 2025-05-16 | 2025-05-16 |
| March 10, 2025 | $1.50 | 2025-02-14 | 2025-02-14 |
| December 10, 2024 | $1.30 | 2024-11-15 | 2024-11-15 |
| September 10, 2024 | $1.30 | 2024-08-15 | 2024-08-15 |
Dividends Summary
- Eli Lilly & Co. has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 10 days ago, on September 10, 2025
- The highest dividend payed out to investors during this period was $1.5 per share
- The average dividend paid during this period was $0.64 per share.
Company News
Eli Lilly is advancing its oral GLP-1 drug candidate with potential FDA fast-track review, signaling a potential breakthrough in diabetes and obesity treatment while expanding U.S. manufacturing capabilities.
Japan's auto-injectors market for GLP-1 receptor agonists is projected to grow from $137.7 million in 2025 to $292.9 million by 2038, driven by rising type 2 diabetes and obesity cases, and increasing demand for convenient at-home medication delivery methods.
German private bank Berenberg upgraded Novo Nordisk to 'buy', arguing that market expectations have reset and the stock is now more attractively valued after previous challenges in the weight loss drug market.
GSK announced a $30 billion investment in US research, development, and manufacturing over five years, including a new $1.2 billion biologics factory in Pennsylvania for respiratory and cancer treatments.
Novo Nordisk and Eli Lilly have both cut prices on their weight-loss drugs Wegovy and Zepbound, respectively, in an apparent price war to attract more customers.
